JP2010524939A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524939A5
JP2010524939A5 JP2010504079A JP2010504079A JP2010524939A5 JP 2010524939 A5 JP2010524939 A5 JP 2010524939A5 JP 2010504079 A JP2010504079 A JP 2010504079A JP 2010504079 A JP2010504079 A JP 2010504079A JP 2010524939 A5 JP2010524939 A5 JP 2010524939A5
Authority
JP
Japan
Prior art keywords
carbons
nuclear receptor
alkyl
receptor binding
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504079A
Other languages
English (en)
Japanese (ja)
Other versions
JP5815237B2 (ja
JP2010524939A (ja
Filing date
Publication date
Priority claimed from US11/785,251 external-priority patent/US8158828B2/en
Application filed filed Critical
Publication of JP2010524939A publication Critical patent/JP2010524939A/ja
Publication of JP2010524939A5 publication Critical patent/JP2010524939A5/ja
Application granted granted Critical
Publication of JP5815237B2 publication Critical patent/JP5815237B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504079A 2007-04-16 2008-04-16 核内受容体結合剤 Expired - Fee Related JP5815237B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/785,251 2007-04-16
US11/785,251 US8158828B2 (en) 2005-11-28 2007-04-16 Nuclear receptor binding agents
PCT/US2008/004908 WO2008130571A1 (en) 2007-04-16 2008-04-16 Nuclear receptor binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014033091A Division JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Publications (3)

Publication Number Publication Date
JP2010524939A JP2010524939A (ja) 2010-07-22
JP2010524939A5 true JP2010524939A5 (enExample) 2011-06-02
JP5815237B2 JP5815237B2 (ja) 2015-11-17

Family

ID=39876311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010504079A Expired - Fee Related JP5815237B2 (ja) 2007-04-16 2008-04-16 核内受容体結合剤
JP2014033091A Expired - Fee Related JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014033091A Expired - Fee Related JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Country Status (4)

Country Link
US (1) US8158828B2 (enExample)
JP (2) JP5815237B2 (enExample)
KR (2) KR101563609B1 (enExample)
WO (1) WO2008130571A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
JP2010528002A (ja) * 2006-12-29 2010-08-19 オステオジェネックス インコーポレイテッド Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
US20090130232A1 (en) * 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
WO2009076548A1 (en) * 2007-12-13 2009-06-18 Cytori Therapeutics, Inc. Methods of inhibiting tumor development using adipose-derived regenerative cells
US8871751B2 (en) * 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
US20100130457A1 (en) * 2008-11-14 2010-05-27 Immune Control, Inc. Phenothiazine Derivatives for Treatment of Asthma
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2013043304A1 (en) * 2009-02-23 2013-03-28 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US20140057946A1 (en) * 2012-08-23 2014-02-27 Gtx Estrogen receptor ligands and methods of use thereof
CN102413692B (zh) * 2009-02-23 2015-01-07 Gtx公司 雌激素受体配体及其使用方法
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
ES2907862T3 (es) * 2009-12-10 2022-04-26 Univ Columbia Activadores de histona acetiltransferasa y usos de los mismos
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP3323813B1 (en) 2010-12-22 2020-08-26 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and uses thereof
CN103763921B (zh) 2011-06-10 2017-03-15 纽约市哥伦比亚大学理事会 组蛋白乙酰转移酶激活剂的用途
CN103957706A (zh) * 2011-08-23 2014-07-30 Gtx公司 雌激素受体配体以及其使用方法
CN104024371B (zh) * 2011-11-01 2015-11-25 默克专利有限公司 有机电致发光器件
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
HRP20201463T1 (hr) 2012-07-13 2021-04-02 Oncternal Therapeutics, Inc. Postupak liječenja raka dojke selektivnim modulatorom androgenskog receptora (sarm)
CN104797933A (zh) 2012-09-07 2015-07-22 阿尔伯达大学董事会 用于诊断发炎性肝病的方法和组合物
WO2014182944A1 (en) * 2013-05-08 2014-11-13 Mangat Harpal S Compositions and method for treatment of ischemic neuronal reperfusion injury
MX382930B (es) * 2014-07-24 2025-03-13 Aspen Park Pharmaceuticals Inc Tratamiento con cis-clomifeno de sofocos y pérdida ósea inducidos por privación de andrógeno terapéutica.
US20220054429A1 (en) * 2015-10-27 2022-02-24 Jay Pharma, Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2018208633A1 (en) * 2017-05-07 2018-11-15 China Medical University Methods and compositions for treating withdrawal syndrome
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE269213C (enExample)
US3413339A (en) * 1964-06-18 1968-11-26 Parke Davis & Co Amine compounds and methods for their production
FR1536400A (fr) 1967-07-05 1968-08-16 Salicylanilides
US3625972A (en) * 1968-07-03 1971-12-07 Sterling Drug Inc N-phenylbenzanilides
US3960886A (en) * 1968-07-03 1976-06-01 Sterling Drug Inc. Substituted N-arylanilines
FR2140645A1 (en) 1971-06-11 1973-01-19 Grace W R Ltd Oxidation stabilised ester lubricants - contg mixed tert aromatic amines
US3838131A (en) * 1972-04-03 1974-09-24 Pfizer Di(dialkylamino alkoxy)phenanthridines as antiviral agents
US3838134A (en) * 1972-04-03 1974-09-24 G Gauthier Phenanthridinones as antiviral agents
US4373017A (en) * 1980-03-05 1983-02-08 Konishiroku Photo Industry Co., Ltd. Photosensitive compound and photosensitive material containing it
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
ES2099206T3 (es) 1991-02-21 1997-05-16 Sankyo Co Derivados de benceno que favorecen la produccion del factor de crecimiento de los nervios humanos.
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
EP0783303B1 (en) * 1994-09-16 2002-11-27 President And Fellows Of Harvard College Use of aromatic halides for treating mammalian cell proliferation
GB9518994D0 (en) 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
AU1730497A (en) 1996-02-17 1997-09-02 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
DE69734983T2 (de) * 1996-03-20 2006-09-07 President And Fellows Of Harvard College, Cambridge Triarylmethanverbindungen zur behandlung von krebs, aktinischer keratose und kaposisarkom
US20020156301A1 (en) * 1997-06-17 2002-10-24 Sumitomo Chemical Co., Ltd. Triphenylmethane derivatives and use thereof
JPH1171332A (ja) * 1997-06-17 1999-03-16 Sumitomo Chem Co Ltd トリフェニルメタン誘導体およびその用途
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6166013A (en) * 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
AU4128800A (en) * 1999-04-16 2000-11-02 Astrazeneca Ab Estrogen receptor-beta ligands
JP4320089B2 (ja) * 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
DE19961372A1 (de) 1999-12-17 2001-06-21 Merck Patent Gmbh Verfahren zur Herstellung kombinatorischer Bibliotheken arylsubstituierter Amine
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
WO2002028853A1 (en) 2000-10-02 2002-04-11 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
KR20030093240A (ko) * 2001-03-16 2003-12-06 이데미쓰 고산 가부시키가이샤 방향족 아미노 화합물의 제조방법
JP2002322162A (ja) 2001-04-26 2002-11-08 Kyowa Hakko Kogyo Co Ltd チアゾリジン誘導体
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
EA200400744A1 (ru) * 2001-11-29 2005-02-24 Джи Ти Икс, ИНК. Предупреждение и лечение остеопороза, вызванного депривацией андрогенов
WO2004009552A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
CA2499490A1 (en) 2002-09-20 2004-04-01 Pfizer Products Inc. Amide and sulfonamide ligands for the estrogen receptor
BR0316098A (pt) * 2002-11-08 2005-09-27 Huawei Tech Co Ltd Método, sistema, e um terminal para executar a interação de informações de apresentação dos usuários de lan sem fio
JP2004307380A (ja) 2003-04-04 2004-11-04 Mitsubishi Chemicals Corp 新規化合物、電荷輸送材料、有機電界発光素子材料および有機電界発光素子
US7601739B2 (en) * 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
AU2007275736A1 (en) * 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof

Similar Documents

Publication Publication Date Title
JP2010524939A5 (enExample)
RU2016103139A (ru) Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
JP2013513613A5 (enExample)
RU2434865C2 (ru) Аналоги тетрагидрохинолина в качестве мускариновых агонистов
JP2011502956A5 (enExample)
RU2012105467A (ru) Триазолопиридиновое соединение и его действие в качестве ингибитора пролилгидроксилазы и индуктора выработки эритропоэтина
JP2013544860A5 (enExample)
JP2012530758A5 (enExample)
RU2012137501A (ru) Сигма-лиганды для применения при профилактике и/или лечении послеоперационной боли
JP2011527334A5 (enExample)
JP2004524316A5 (enExample)
JP2011137006A5 (enExample)
JP2010536887A5 (enExample)
JP2006516622A5 (enExample)
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2011521938A5 (enExample)
RU2015142102A (ru) Соединение для лечения рака
JP2013520473A5 (enExample)
JP2014015465A5 (enExample)
TNSN07016A1 (en) Indole-2-carboxamidine derivatives as nmda receptor antagonists
JP2013508288A5 (enExample)
RU2015147509A (ru) Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
NO20080877L (no) Fremgangsmater for behandling av substansrelaterte forstyrrelser
RU2011137324A (ru) Лиганды рецепторов эстрогенов и способы их применения
JP2010155827A5 (enExample)